Introduction
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph þ ALL) is a well-defined subset of B-precursor ALL. 1 Patients with Ph þ ALL, when compared with those who have non-Ph þ ALL, are older and present with a higher white blood cell (WBC) counts. [2] [3] [4] [5] Intensive multicycle combination chemotherapy, the standard treatment for B-precursor ALL (including Ph þ ALL), has improved the outcomes of patients with B-precursor ALL in general and results in complete remission (CR) in more than 90% of patients and long-term survival in about 50%. [6] [7] [8] [9] [10] [11] However, in patients with Ph þ ALL, the prognosis (a similar or slightly inferior CR rate, a significantly shorter median CR duration (less than 12 months), and rare long-term survival) remains poor. 12, 13 The short duration of CR in those with Ph þ ALL suggests a rapid development of secondary resistance to chemotherapeutic agents in Ph þ ALL cells. Allogeneic hematopoietic cell transplantation (HCT) is the only currently available curative modality for Ph þ ALL when performed during the first CR status. [14] [15] [16] [17] [18] Imatinib is an orally administered tyrosine kinase inhibitor that has shown excellent antileukemic activity in CML; it has become the standard treatment for newly diagnosed chronicphase CML. 19, 20 When administered to patients experiencing a lymphoid blastic crisis of CML or recurrent or refractory Ph þ ALL, however, imatinib has produced a modest CR rate (40-50%) and, more importantly, a median duration of remission of only 2-4 months. [21] [22] [23] In contrast to chronic phase-CML, Ph þ ALL is a rapidly progressing disease, and additional chromosomal abnormalities are identified in most patients at diagnosis. 1, 5 Treatment with imatinib alone, even in newly diagnosed cases of Ph þ ALL, is not likely to produce long-term disease control. However, because of the nonoverlapping toxicity profiles of imatinib and cytotoxic agents, imatinib may be an ideal agent that can be added to currently available chemotherapy for Ph þ ALL. The added blockage of BCR-ABL tyrosine kinase by imatinib may delay or prevent the development of secondary resistance to chemotherapeutic agents in Ph þ ALL cells, thus prolonging leukemia-free survival. Several studies have explored the feasibility and effectiveness of treatment with combination chemotherapy plus imatinib. However, those studies vary with respect to the timing of initiation of imatinib, and the dose and duration of administration of imatinib. [24] [25] [26] Herein, we describe the results of a single-center prospective study in which patients with newly diagnosed Ph þ ALL were treated with intensive multicycle combination chemotherapy plus daily imatinib 600 mg (for remission induction) or 400 mg (for consolidation courses). The clinical effect of the addition of imatinib to combination chemotherapy in terms of the CR rate, remission duration and patient survival was evaluated by comparing our study results with those of a historical cohort of patients with Ph þ ALL who had been treated with same regimen of combination chemotherapy but without imatinib.
Patients and methods
The treatment protocol for the study of the effect of combination chemotherapy plus imatinib was initiated in December 2001, and 20 patients enrolled before May 2004. All subjects met the following criteria for enrollment; age of 15 years or older, a diagnosis of ALL or acute mixed lineage leukemia with BCR-ABL transcript detected by reverse transcription-polymerase chain reaction (RT-PCR), a Karnofsky performance scale of 70 or more, and adequate organ function (total bilirubin, o2.0 mg/dl; aspartate aminotransferase (AST), o100 U/l; creatinine, o2.0 mg/dl; and cardiac ejection fraction, 445% by multigated blood pool scan). The protocol was approved by the institutional review board of the Asan Medical Center, and all patients signed informed consent. 2 ) intrathecally during induction and the first consolidation course without risk stratification.
Combined treatment of combination chemotherapy plus imatinib
As soon as the positive result for BCR-ABL detected by RT-PCR became available, a daily oral dosage of imatinib (Gleevec, Novartis Pharma, Basel, Switzerland) was initiated. Originally, imatinib was administered daily in the dosages of 600 mg for 14 days during remission induction chemotherapy and 400 mg for 14 days from day 1 of each course of consolidation chemotherapy. After the enrollment of 12 patients, the protocol was amended and imatinib was administered throughout the induction chemotherapy (600 mg daily) and consolidation courses (400 mg daily). After the completion of consolidation therapy, maintenance treatment was planned with imatinib 400 mg orally for 2 years.
Definitions and toxicity monitoring
'CR' was defined as the recovery of a peripheral blood absolute neutrophil count (ANC) of 41000/ml and a platelet count of 4100 000/ml as well as bone marrow aspirate showing active regeneration of blood cells with 5% or fewer blasts. 'Recurrence' was defined as the presence of leukemic cells in the bone marrow aspirate (45%) or extramedullary sites in patients with previously documented CR. Toxicities of treatment with imatinib and chemotherapy were graded according to the Common Toxicity Criteria, version 2.0 (National Cancer Institute, Bethesda, MD, USA). Treatment with imatinib was interrupted in patients who exhibited a grade-3 or greater toxicity until recovery to either grade-1 toxicity or normal. Therapy with imatinib was not, however, interrupted for myelosuppression thought to be related to combination chemotherapy.
Allogeneic HCT
In total, 17 patients in the study underwent allogeneic HCT. The protocol for allogeneic HCT was approved by the Institutional Review Board, and the patients and donors provided written informed consent. A total of 15 patients were in their first CR status at the time of HCT and had received a median of 2 courses (range, 1-8 courses) of consolidation therapy. The remaining two patients were in their second CR status. In 16 patients, imatinib was administered until the initiation of conditioning therapy for HCT. Imatinib was not given after HCT unless molecular or hematologic evidence of persistent or recurrent leukemia was noted. Conditioning regimens were as follows: BuCy (busulfan 3.2 mg/kg/day i.v. or 4 mg/kg orally for 4 days, then cyclophosphamide 60 mg/kg/day i.v. for 2 days) in 14 patients and reduced intensity BuFluATG (busulfan 3.2 mg/ kg/day i.v. for 2 days, fludarabine 30 mg/m 2 /day for 6 days, and rabbit antithymocyte globulin 3 mg/kg/day i.v. for 3 days) in 3. The donor hematopoietic cells were T-cell-replete and were from human leukocyte antigen (HLA)-matched siblings in seven patients, HLA-matched unrelated donors in nine, and an HLAhaploidentical mother in one. The regimen for the prophylaxis of graft-versus-host disease (GVHD) was cyclosporine with (12 patients) or without (five patients) a short course of i.v. methotrexate.
Historical cohort of patients treated with combination chemotherapy without imatinib
A total of 18 patients in the historical cohort were diagnosed between July 1995 and April 2001 as having Ph þ ALL and were treated with the same combination chemotherapy described above but without imatinib. Five patients in this group underwent allogeneic HCT after conditioning with BuCy (with oral busulfan) while in their first (three patients) or second (two patients) CR status. The donors were HLA-matched siblings. The GVHD prophylaxis regimen included cyclosporine plus a short course of methotrexate.
Qualitative and quantitative RT-PCR for BCR-ABL transcripts
Qualitative RT-PCR assays for BCR-ABL were performed using multiplex primers according to standard methods. 27 Serial assays of a mixture of K562 and negative control (HL-60) cDNA showed that the sensitivity of RT-PCR was at least 1 in 10 4 . Bone marrow samples were used in those assays at diagnosis and CR, and, in patients who underwent allogeneic HCT, at the initiation of conditioning chemotherapy and bone marrow recovery. Peripheral blood mononuclear cells were used in the assays after each courses of consolidation therapy, and in patients who underwent allogeneic HCT, at 2 and 3 months, and every 3 months thereafter. Quantitation of BCR-ABL transcripts was performed retrospectively on stored RNA samples using LightCycler Technology (Roche Diagnostics, Mannheim, Germany) as described by Kreuzer et al. 28 The amount of BCR-ABL mRNA was expressed relative to the amount of glucose-6-phosphate dehydrogenase (G6PDH) mRNA.
Statistical analyses
Categorical variables were compared using w 2 test. In both the study and historical cohorts of patients, CR duration was measured from the documentation of CR to the recurrence of disease or the last follow-up. Patients who died while in CR were censored. Overall survival was measured from the initiation of chemotherapy to the last follow-up or death from any causes. The CR duration and overall survival curves were plotted according to the Kaplan-Meier method and were compared using log-rank test.
Results

Patient characteristics
Clinical characteristics of the patients studied (13 men and seven women; median age, 37 years (range, 15-67 years)) and their treatment outcomes are summarized in Table 1 . The median WBC count at the time of diagnosis was 59.8 Â 10 3 /ml (range, 2.7-193.4 Â 10 3 /ml). On chromosomal analysis, 16 of 19 evaluable patients showed the Philadelphia chromosome plus additional chromosomal abnormalities. A total of 13 patients had e1a2 type BCR-ABL, while seven had b2a2 or b3a2 type. One patient (no. 18) had been treated at another hospital with combination chemotherapy of cyclophosphamide, vincristine, doxorubicin, and dexamethasone and was in a refractory state at the time of entry into our study protocol. All the other patients were chemotherapy-naïve.
Clinical efficacy of combined treatment of combination chemotherapy plus imatinib
Imatinib was begun at a median of 3 days (range, 0-7 days) after the initiation of combination chemotherapy. As shown in Table 1 and Figure 1 , one patient died 13 days after the initiation of induction therapy because of sepsis (methicillinresistant Staphylococcus epidermidis). All remaining of 19 evaluable patients achieved CR (median time to CR, 28 days; range, 24-74 days). Of those 19 patients, 17 showed rapid clearance of leukemic cells from the bone marrow on day-14 bone marrow examination.
After a median follow-up of surviving patients of 799 days (range, 275-991 days), six of 19 patients who had achieved CR experienced a recurrence of disease. The median duration of CR was 821 days (range, 89-964 þ days, Figure 2a) . Two patients showed recurrence within 100 days after achieving CR. One patient without an HLA-compatible hematopoietic cell donor experienced a recurrence in the leptomeninges 341 days after achieving CR. In three patients, Ph þ ALL recurred 246-617 days after undergoing allogeneic HCT in the first CR status. The recurrence pattern and its course in relation to serial BCR-ABL monitoring are described subsequently in this article. The patient showed persistent positive results on RT-PCR for BCR-ABL after allogeneic HCT. The cyclosporine dosage was tapered rapidly, and imatinib was reintroduced at a dosage 400 mg daily with subsequent achievement of molecular remission by 9 months after HCT. The patient remained in molecular remission for more than 11 months, after which a full-blown hematologic recurrence of acute leukemia developed. The patient died on the fifth day of salvage chemotherapy with cytarabine, mitoxantrone, vincristine, and methyl-prednisolone. RT-PCR testing for BCR-ABL, which was performed 1 year after HCT was positive and the patient was treated with cyclosporine withdrawal and the reintroduction of imatinib 400 mg daily. The patient remained in molecular remission on imatinib for about 8 months, after which a hematologic recurrence of acute leukemia developed. Subsequently, the patient underwent salvage chemotherapy with cytarabine, mitoxantrone, and etoposide and died 30 days later from sepsis. The recurrent disease was confined to the leptomeninges. The patient was treated with intrathecal chemotherapy consisting of methotrexate and cytarabine, and clearance of leukemic blast from the cerebrospinal fluid occurred. e Treatment with imatinib 600 mg daily was reintroduced, and the patient achieved hematologic CR. Subsequently, the patient received a maternal donor leukocyte infusion and remains in molecular disease remission at the time of this writing. The recurrence occurred in the bone marrow and leptomeninges. The patient was treated with cyclosporine withdrawal, imatinib 400 mg daily, intrathecal methotrexate/cytarabine, and craniospinal irradiation and achieved clearance of leukemic blasts from the bone marrow and cerebrospinal fluid. Subsequently, the patient received a donor leukocyte infusion and remains molecular disease remission at the time of this writing. g RT-PCR for BCR-ABL performed 3 months after HCT was positive, and the patient was treated with cyclosporine withdrawal and reintroduction of treatment with imatinib 400 mg daily. Despite that treatment and after a short period of PCR negativity, the patient developed a full-blown hematologic recurrence of disease 5 months later while on imatinib and died, despite salvage chemotherapy.
The median overall patient survival was 894 days (range, 13 to 991 þ days, Figure 2b ). The causes of eight deaths in the study were sepsis during induction (1), recurrent leukemia (4), and transplantation-related complications (3) . At the time of this writing, two patients were surviving without evidence of leukemia after having undergone salvage treatment ( Table 1) .
The historical cohort consisted of eight men and 10 women (median age, 44 years; range 20-65 years). There was no significant difference in age, sex, WBC count at diagnosis, or proportion with additional chromosomal changes between the study subjects and the historical cohort. Significantly more patients in the historical cohort demonstrated persistent leukemic blasts on day 14 bone marrow examination and required additional treatment with daunorubicin than did patients in the study group (12/18, P ¼ 0.001). In total, 15 of 18 patients (83%) in the historical cohort achieved CR (median time to CR, 29 days; range, 27-74 days; P ¼ 0.235 when compared to the study group; Figure 1 ). The disease recurred in 14 of 15 patients (median CR duration, 284 days; range, 10-1573 days). The duration of CR was significantly longer for the study cohort of patients when compared with the historical cohort (P ¼ 0.009; Figure 2a ). In total, 16 patients in the historical cohort died (median overall survival, 390 days; range, 32-1972 days). Again, overall survival was significantly longer in the study cohort than in the historical cohort (P ¼ 0.019; Figure 2b ).
Toxicities of combined treatment of combination chemotherapy plus imatinib
In all, 20 patients in the study received 20 courses of remission induction therapy, 29 courses of consolidation A regimen, and 22 courses of consolidation B regimen and all were evaluated for the toxicities (Table 2) . During remission induction treatment with combined chemotherapy plus imatinib, all patients experienced grade-4 neutropenia with 10 requiring antibiotics treatment for febrile episodes. Despite the coadministration of imatinib, however, bone marrow recovery was not delayed, regardless of the duration of imatinib administration. In 12 patients who received imatinib for 14 days and achieved CR, the median recovery time to an ANC of 41000/ml was 23 days (range, 19-46 days). In seven patients who received imatinib continuously throughout induction chemotherapy, the median recovery time to an ANC41000/ml was 21 days (range, 19-30 days).
Four patients experienced grades-3 or higher hyperbilirubinemia during induction therapy that resolved after the interruption of L-asparaginase and imatinib administration. Other grade-3 or -4 toxicities (nausea, epigastric pain, myalgia, liver enzyme abnormalities, and weight gain) were observed in a few patients.
Serial RT-PCR
The amount of BCR-ABL transcript was measured retrospectively on stored serial RNA samples and is presented in Figure 3 . At the time of diagnosis, the median BCR-ABL/G6PDH ratio was Of 17 patients who underwent allogeneic HCT in the study, one patient (no. 1) showed persistent molecular evidence of Ph þ ALL and two patients (nos. 5 and 13) showed new molecular evidence of disease; all were treated with a rapid withdrawal of cyclosporine and reintroduction of imatinib 400 mg daily. Despite treatment, all three of those patients developed a full-blown hematologic recurrence of Ph þ ALL within 1 year and died. Two patients experienced a hematologic recurrence of Ph þ ALL without prior molecular evidence of disease, and one of those two exhibited leptomeningeal involvement as well. Those two patients were successfully treated with various measures of salvage therapy, including imatinib, intrathecal chemotherapy, cranial irradiation and subsequent donor leukocyte infusion.
Discussion
Several observations made in our study suggested that imatinib enhanced the antileukemic effect of combination chemotherapy in patients with Ph þ ALL. After remission induction therapy with combination chemotherapy plus imatinib, all 19 evaluable patients achieved CR. Only two of those 19 patients showed evidence of residual leukemic blasts on day 14 bone marrow examination, which suggests that this combined treatment regimen cleared leukemic blasts rapidly. At CR, eight of 16 evaluable patients (50%) demonstrated a negative PCR result for BCR-ABL, with a median log-reduction of BCR-ABL transcript of 2.41. Although direct comparison was not possible, this degree of antileukemic effect during remission induction has not been reported when Ph þ ALL is treated with combination chemotherapy alone. As shown in our report, when the same regimen of combination chemotherapy was used without imatinib in a historical cohort of patients with Ph þ ALL, 12 of 18 patients demonstrated persistent leukemic cells on day 14 bone marrow Kaplan-Meier plots of remission duration (a) and overall patient survival (b). Six of 19 study subjects vs 14 of 15 historical cohort patients experienced a recurrence of acute leukemia (median CR durations, 821 vs 284 days, respectively; P ¼ 0.009). Eight of 20 study subjects vs 16 of 18 historical cohort patients died (median overall survival, 894 vs 390 days, respectively; P ¼ 0.019). Table 2 Toxicities of combined treatment during remission induction therapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Toxicities
Induction therapy with imatinib 600 mg daily For 14 days (n ¼ 12)
Nadir ANC (ml À1
AST (U/l)
Grade 1 7 3 Grade 2 1 1 Grade 3 1 2
ALT (U/l)
Grade 1 4 2 Grade 2 4 2 Grade 3 3 2
Weight gain (%)
ANC ¼ absolute neutrophil count; AST ¼aspartate aminotransferase; ALT ¼alanine aminotransferase. a Numbers denote the number of treatment courses associated with the respective category of toxicity.
examination, and three of those patients eventually failed to achieve CR because of refractory disease. In an analysis of 154 patients with Ph þ ALL, 13 45% of patients exhibited refractory disease after 4 weeks of treatment with intensive multiagent combination chemotherapy. In total, 27% of those patients who achieved CR evidenced negative RT-PCR results for BCR-ABL. In another report 29 of patients with Ph þ ALL who were treated with a combination chemotherapy regimen used in the German Multicenter Study Group for Adult ALL, the median BCR-ABL transcript log reduction ranged from only 1 to 1.8 when CR was achieved.
In our study, another positive effect of the addition of imatinib to combination chemotherapy in patients with Ph þ ALL was the significant prolongation of CR. Of 19 patients who achieved CR, only two experienced recurrent disease within 4 months after the achievement of CR. This resulted in a relatively large number of patients (15) undergoing allogeneic HCT maintaining CR. Compared with the historical cohort of patients, the overall CR duration was prolonged by 2.9-fold and patient survival was prolonged by 2.3-fold.
The toxicities of combined treatment approach in our study were mainly attributed to the effects of combination chemotherapy. During remission induction treatment, all patients experienced severe neutropenia with a nadir ANC of o100/ml and required prophylactic platelet transfusion. However, bone marrow recovery was not delayed despite imatinib administration, even in patients who received imatinib throughout the remission induction course. Grades 3-4 reversible hyperbilirubinemia occurred in four patients during remission induction, which was more likely due to treatment with L-asparaginase than to imatinib therapy.
Two recent trials explored combined treatment of combination chemotherapy plus upfront imatinib and reported similar findings as our study. Patients in the study by Thomas et al achieved CR and only two patients required two cycles of induction therapy. The molecular CR rate in 19 patients who did not undergo allogeneic HCT was 50%. Only two patients died from leukemia with a 2-year disease survival rate of 87%. In a trial by Towatari et al, 25 patients received induction chemotherapy with cyclophosphamide, daunorubicin, vincristine, and predinisolone plus imatinib 600 mg, which was given daily for 56 days during remission induction and then in a dosage of 400 mg daily for 28 days during alternate consolidation courses. In total, 23 of 24 patients (96%) achieved CR after single cycle of chemotherapy, with a molecular CR rate of 50%. In four patients, disease recurred within 1 year, and 15 patients (63%) were able to undergo allogeneic HCT maintaining their first CR status. In neither of above studies, an unexpected toxicity or prolonged myelosuppression was reported. The achievement of molecular CR in over the half of patients with newly diagnosed Ph þ ALL by combined treatment of combination chemotherapy plus imatinib is remarkable. The durability of molecular CR, as well as the role of allogeneic HCT, in this subset of patients needs to be investigated in future clinical trials with larger number of patients.
In contrast to our study, in a study by Lee et al, 26 imatinib was initiated after the patients with newly diagnosed Ph þ ALL achieved CR after combination chemotherapy with cyclophosphamide, idarubicin, vincristine, and dexamethasone. In total, 23 of 29 patients (79%) achieved CR. Imatinib, given at the dose of 400-600 mg daily during consolidation chemotherapy, decreased the BCR-ABL transcript effectively as measured by quantitative RT-PCR and seemed to prolong CR duration. High CR rate (over 90%) without significant added toxicity, observed in studies including ours in which imatinib was given as a part of remission induction therapy, suggested that the earlier introduction of imatinib might be a better treatment strategy for patients with newly diagnosed Ph þ ALL. It should be noted that although our data, along with the corroborating data from other groups, suggest that imatinib can be added to currently available combination therapy for Ph þ ALL without significantly increasing toxicity and can potentiate clinical benefits, those conclusions are based on the comparisons with historical cohorts of patients and are thus subject to possible bias. Furthermore, at this time, the relative contribution in the prolongation of CR by the antileukemic effect of imatinib itself and the effect of more patients undergoing allogeneic HCT during the first CR remains to be discerned.
In future trials of combination chemotherapy plus imatinib, the following factors may be considered. In view of the dosedependent antileukemic effect of imatinib in CML, 30 increasing the dosage of imatinib may be tried during induction treatment with careful monitoring of toxicities and with one of the endpoints of the study being the proportion of patients achieving negative BCR-ABL at CR. Likewise, the effects of a daily dosage of imatinib greater than 400 mg should be examined during the consolidation chemotherapy phase. In two patients in our study and in three in the study by Towatari et al, 25 disease recurred within 5 months of CR while the patients were receiving an intermittent dose of imatinib during consolidation treatment. The benefit of administering imatinib continuously during consolidation therapy should also be examined.
The optimum regimen for combination chemotherapy, including the role of L-asparaginase, in the combined approach for the treatment of Ph þ ALL must be defined. In this study, L-asparaginase rather than imatinib was thought to be the cause of grade 3-4 hyperbilirubinemia that necessitated the interruption or delay of imatinib administration. In older patients, who are more susceptible to the myelosuppressive effects of antileukemic therapy, an attenuated chemotherapy regimen combined with imatinib may decrease treatment-related morbidity and mortality.
Of the six initial recurrences of Ph þ ALL observed in our study, three involved leptomeningeal disease with or without bone marrow involvement, despite prior central nervous system prophylaxis with intrathecally administered methotrexate. Poor penetration of imatinib into the cerebrospinal fluid has been documented. 31 As combination chemotherapy plus imatinib results in an overall reduction in the recurrence of Ph þ ALL, we may encounter a relative upsurge in the incidence of leptomeningeal disease. Other approaches for central nervous system prophylaxis, including the potential for intrathecal administration of tyrosine kinase inhibitors, should be considered.
In conclusion, we have observed clinically beneficial effects (induction of rapid CR, prolongation of CR and patient survival) when imatinib was added to currently available intensive multicycle combination chemotherapy for patients with Ph þ ALL. The toxic sequelae of combined treatment were manageable. Further studies with larger numbers of patients and longer follow-ups are warranted.
